Objectives: This multicentre, parallel group, double-blind, double-dummy, randomised 24-week study was designed to compare the efficacy of salmeterol/fluticasone propionate combination (SFC) 50/250 mg one inhalation twice daily (bid) with formoterol/budesonide combination (FBC) 6/200 mg two inhalations bid in patients with persistent asthma, currently receiving 1000-2000 mg/day of inhaled corticosteroids. Methods: The intent-to-treat population comprised 694 patients in the SFC group and 697 patients in the FBC group. Results: The primary endpoint, mean rate of all exacerbations over 24 weeks, was similar in both treatment groups (SFC: 2.69; FBC: 2.79; SFC/FBC ratio 0.96; 95% CL 0.84, 1.10; P ¼ 0:571). A reduction in the rate of exacerbations over time was observed in both treatment groups. Overall, there was a 30% lower annual rate of moderate/severe exacerbations in the SFC group compared with the FBC group (95% CI 0-49%, 52% reduction vs. 1% increase; P ¼ 0:059). This effect increased with time: in weeks 17-24 the moderate/severe exacerbation rate was 57% lower in the SFC group compared with the FBC group (95% CI 21-77% reduction; P ¼ 0:006). Similar improvements in lung function, asthma symptoms and rescue medication usage were seen with both treatments and both were well tolerated. Conclusions: Twice-daily treatment with SFC and FBC over 6 months significantly improved asthma symptoms and lung function in patients with persistent asthma. The rate of exacerbations was significantly reduced over time on both treatments but SFC was found to be significantly superior to FBC in reducing the rate of moderate/severe exacerbations with sustained treatment.
Introduction
It is now well recognised that adding a long-acting b 2 -agonist (LABA) to inhaled corticosteroid (ICS) therapy is more effective than ICS alone, even at double the dose, in improving asthma control in symptomatic asthmatic patients. [1] [2] [3] [4] The co-prescribing of an ICS and a LABA is now an integral part of asthma treatment guidelines. 5, 6 Combination products, containing both an ICS and a LABA in one inhaler, have been available for a few years and may help to improve patient acceptability and compliance in taking both therapies. The salmeterol/fluticasone propionate combination (SFC) Seretide s /Advair s /Viani s (GlaxoSmithKline, Middlesex, UK), contains the LABA salmeterol xinafoate 50 mg and the ICS fluticasone propionate (FP) at one of three doses, 100 mg, 250 mg or 500 mg, in a single Diskus/Accuhaler s (GlaxoSmithKline, Middlesex, UK). The formoterol/budesonide combination (FBC) Symbicort s (AstraZeneca, UK), contains the LABA formoterol 6 mg and the ICS budesonide at one of two doses, 100 mg or 200 mg, in a single Turbuhaler s (AstraZeneca, UK). Studies have shown that, compared with FP alone, SFC is more effective 7, 8 and compared with FP and salmeterol given concurrently in separate inhalers, SFC is at least as effective and well tolerated. 9, 10 The Formoterol And Corticosteroids Establishing Therapy (FACET) study showed that formoterol and budesonide given concurrently were more effective than budesonide alone. 11 A comparison of SFC 50/250 mg twice daily (bid) versus formoterol 12 mg bid and budesonide 800 mg bid given concurrently showed that SFC was at least as effective as formoterol and budesonide in improving morning peak expiratory flow (PEF), and more effective in reducing exacerbations and symptoms at night. 12 There are very few studies that have compared the efficacy of the two combination products SFC and FBC directly. The primary aim of the current study was to compare the efficacy of SFC delivered via Diskus/Accuhaler 50/250 mg one inhalation bid with FBC delivered via Turbuhaler 6/200 mg two inhalations bid in reducing the rate of exacerbations over a 6-month study period in patients with persistent asthma. The doses of SFC and FBC chosen are those recommended in this patient population.
Methods

Study design
This was a randomised, double-blind, doubledummy, parallel group study, conducted in 178 centres in 18 countries. Following a 2-week run-in period, patients were randomised to receive either SFC or FBC for 24 weeks. Patients attended study visits at weeks 4, 8, 16 and 24 of the treatment period and a post-study safety assessment was performed by telephone, approximately 7 days after completion or withdrawal. The study protocol was approved by a national, regional or investigational centre scientific ethics committee or institutional review board, and was conducted in accordance with International Conference on Harmonization Good Clinical Practice (ICH GCP) and the Declaration of Helsinki (2000) . Written informed consent was obtained from each patient prior to study enrolment.
Study population
Those eligible were male or female outpatients aged 18 years or over, with a documented clinical history of asthma of at least 6 months and who had been receiving 1000-2000 mg/day of beclomethasone dipropionate or equivalent. Combination therapy, if used, was discontinued and replaced with ICS alone, at least 4 weeks prior to study start (screening visit). At the screening visit, patients were required to demonstrate a reversible increase in forced expiratory volume in 1 s (FEV 1 ) of 12% or more, 15 min after inhaling salbutamol 200-400 mg. For entry to the randomised treatment period (baseline), patients were required to demonstrate a reversible increase in FEV 1 of at least 12% (and X200 mL), 15 min after inhaling salbutamol 200-400 mg, and an asthma symptom score (day and night combined) of at least 2 (two or more episodes of symptoms during the day/night) on at least 4 of the last 7 evaluable days of the run-in period. Patients were excluded from the study if they had: suffered an upper or lower respiratory tract infection or an acute asthma exacerbation (requiring emergency treatment or hospitalisation) within 4 weeks of Visit 1; used oral corticosteroids within 4 weeks or depot steroids within 12 weeks of Visit 1; a pre-bronchodilator FEV 1 of o50% of predicted value; or a smoking history of X10 pack years.
Treatment
Blinded study medication was packed and supplied by GlaxoSmithKline (GSK). All treatment packs contained both Diskus/Accuhaler and Turbuhaler devices (either active Diskus/Accuhaler+placebo Turbuhaler, or active Turbuhaler+placebo Diskus/ Accuhaler) and looked identical. The doubledummy design ensured that both the patients and the investigators remained blind to the active medication being received. Patients were assigned to study treatment in accordance with the randomisation schedule from the Interactive Voice Recognition System, which was part of the GSK System for the Central Allocation of Medication. During the run-in period, patients continued on their current ICS plus salbutamol as required. At Visit 2, eligible patients were randomly assigned to one of the following treatment groups for 24 weeks: The doses of SFC and FBC given were those recommended for this patient population with persistent asthma, and patients were instructed to use the Diskus/Accuhaler followed by the Turbuhaler, both within 2 min of each other, in that order.
Rate of exacerbations
The primary endpoint was the number of all asthma exacerbations experienced by the patient expressed as a rate over the 24-week treatment period. The severity of exacerbations was also recorded. Exacerbations were assessed by the physician at each scheduled visit by reviewing the daily record card (DRC) on which patients were asked to record information about their condition, as well as by asking specific questions about adverse events (AEs). Exacerbation definitions are shown in Table 1 .
Lung function
Morning and evening PEF were recorded on the DRC, prior to the use of rescue or study medication. FEV 1 was measured at each clinic visit and patients were requested not to use short-acting bronchodilators for at least 6 h prior to the measurement being recorded.
Asthma symptoms and rescue medication use
Patients recorded their level of symptoms on the DRC each morning and evening, prior to the use of rescue or study medication. Daytime scores were based on a scale from 0 (no symptoms) to 5 (symptoms so severe that the patient could not go to work or perform normal daily activities), and night-time scores were based on a scale from 0 (no symptoms) to 4 (symptoms so severe that the patient was unable to sleep). The amount of rescue medication used in the previous 12 h was also recorded each morning and evening. 'Well-controlled' asthma
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Safety
The incidence and type of AEs were recorded throughout the study. An AE was defined as any untoward medical occurrence irrespective of causality. Oropharyngeal examinations were conducted at each visit.
Statistical analyses
The total sample size was determined on the basis of anticipated differences between treatments in average asthma exacerbation rate over a 24-week treatment period. Based on data from two previous studies, 11, 12 the average exacerbation rate for FBC Turbuhaler is estimated to be one per patient per 6 months. To detect a difference of 20% in the relative risk of exacerbations between SFC and FBC, at a two-sided a ¼ 0:05 significance level with 90% power using the Normal approximation to the Poisson regression techniques, 525 patients per group were required.
Analysis of the primary and secondary efficacy measures was based on the intent-to-treat (ITT) population. The primary efficacy endpoint, rate of exacerbations over the 24-week treatment period, was analysed using a maximum-likelihood based analysis assuming the Poisson distribution, with time on treatment as an offset variable. The model included adjustments for the effects of gender, country grouping and age. A time effect was noted following the initial analysis, therefore, further analyses were conducted to investigate annualised exacerbation rates over time. The number of exacerbations in each interval (weeks 1-8, weeks 9-16 and weeks 17-24) was counted. Last observation carried forward (LOCF) was used to account for missing data due to early withdrawal from the study. The analysis of these data was performed using Generalised Estimating Equation (GEE) methodology adjusting for the main effects used in the primary analysis, as well as time interval. The number and severity of exacerbations were analysed using logistic (proportional odds) regression. A separate analysis of the rate of moderate/severe exacerbations was also performed following the observation of a numerical imbalance in the numbers of these exacerbations ( Table 2 ). All exacerbation-based analyses were repeated using exacerbation data as strictly defined per protocol, to present a more objective analysis of the data.
Lung function endpoints (FEV 1 and PEF) and symptom scores were analysed using analysis of covariance (ANCOVA) adjusting for baseline, country, gender, age and treatment. The proportion of patients achieving 'well-controlled' asthma was assessed using a two-sided Fisher's exact test. Safety measures were presented as summary statistics.
Results
Patients
A total of 1769 patients were screened for this study, of which 1397 were randomised to treatment: 697 to the SFC group and 700 to the FBC group (Fig. 1) . Six patients were subsequently excluded due to a lack of adherence to ICH GCP and therefore the final ITT population comprised 1391 patients: 694 in the SFC group and 697 in the FBC group. After randomisation, 133 patients (10%) were withdrawn: 71 (10%) from the SFC group and 62 (9%) from the FBC group. Baseline characteristics, including lung function and previous asthma medications, were well matched between the two groups (Table 3) . Patients were recruited from 178 centres in 18 countries. Several centres contributed 6 or less patients to the study, therefore country grouping was used where appropriate. In all efficacy analyses and tests of treatment interactions, country grouping was not significant. This would indicate that the results are valid in several countries.
Exacerbation rates
For the primary endpoint, the adjusted mean rate of all exacerbations over 24 weeks, as recorded by the investigators, was similar in both treatment groups (2.69 for SFC and 2.79 for FBC) ( Table 2 ). The majority of exacerbations were mild. Further analysis of all exacerbations adjusting for time interval, revealed a significant effect of time, such that the rate of all exacerbations across both treatment groups showed a 30% reduction in weeks 9-16 (95% CI 24-36%; Po0:001) and a 36% reduction in weeks 17-24 (95% CI 30-42%; Po0:001) compared with weeks 1-8. From approximately 8 weeks of treatment, the cumulative number of exacerbations, defined as per protocol (PP), was slightly higher in the FBC group compared with the SFC group, and this difference increased as time progressed (Fig. 2a) . However, there was no statistically significant difference between the groups.
Although there was no statistically significant difference between treatments in terms of the severity of exacerbations, a numerical imbalance between the groups in the number of moderate/ severe exacerbations (67 for the SFC group vs. 80 for the FBC group) was observed. Further analysis showed that, adjusting for time, there was a 30% reduction (95% CI 0-49%, 52% reduction (SFC) vs. 1% increase (FBC); P ¼ 0:059) in the incidence of moderate/severe exacerbations between treatment groups with a treatment by-interval effect overall approaching statistical significance (P ¼ 0:055), indicating that there was a difference between treatments over time. A cumulative plot of the number of moderate/severe exacerbations by study day in each treatment group is shown in Fig. 2b . The treatment lines start to diverge after about 3 months of treatment and the difference between the groups increased with time. The difference between the treatment groups was statistically significant at weeks 17-24, where the SFC group showed a 57% (0.105 vs. 0.244, SFC and FBC, respectively, P ¼ 0:006) reduction in the rate of moderate/severe exacerbations compared with the FBC group ( Table 2 and Fig. 3 ).
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Lung function, asthma symptoms and rescue medication use
Both treatment groups showed a steady increase in mean morning PEF and mean FEV 1 during the treatment period ( . A large increase in the mean percentage of symptom-free days/nights and days when no rescue medication was used was also seen in both groups (Table 4 ). There was no statistically significant difference between treatments for these parameters.
'Well-controlled' asthma
The proportion of patients who achieved a week of 'well-controlled' asthma at any point during the 
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Safety measures
Overall, both treatments were shown to be safe and well tolerated. The incidence and type of AEs were similar in both treatment groups and not unexpected in patients with moderate-to-severe asthma. The proportion of patients with at least one AE that started during treatment was 384 (55%) in the SFC group and 377 (54%) in the FBC group.
The incidence of drug-related AEs was o10% in both groups, the most commonly reported drugrelated Only one SAE was considered to be related to the study drug: a severe hoarseness/dysphonia in a patient in the FBC group. The incidence of oral candidiasis was low in each treatment group and none of the occurrences reported were serious. Oral swabs were collected from 14 patients (2%) in each treatment group due to clinical evidence of candidiasis. Of these, 8 patients (1%) in the SFC group and 7 patients (1%) in the FBC group had a positive swab result. 
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Discussion
The primary objective of the EXCEL study was to compare the efficacy of SFC 500/250 mg one inhalation bid with FBC 6/200 mg two inhalations bid in preventing the occurrence of asthma exacerbations in adults with persistent asthma. It is one of the first studies to directly compare the two LABA/ICS combination products, SFC and FBC, in this population of persistent asthmatics over a 6-month treatment period. Overall the study found both treatments to be effective in reducing the rate of exacerbations over 6 months (primary endpoint) and to be equally safe and well tolerated.
It was assumed that the rate of exacerbations would remain constant throughout the 24-week treatment period. However, because there was a clear improvement with time on regular treatment in other endpoints, such as PEF and rescue medication use, a similar treatment effect for the rate of exacerbations was considered possible. Further analyses were carried out to investigate the effect of regular, stable dose treatment on exacerbation rates over time. The interval of 8-week periods used to analyse the time effect of treatment on exacerbation rate was consistent with time intervals used in another study. 13 As the definitions of exacerbations had been clearly stated in the study protocol, the analyses were also performed using exacerbation as strictly defined by the protocol in order to more objectively analyse the data. The results from both sets of data (investigator-defined and protocol-defined exacerbations) showed a significant reduction in the rate of exacerbations over time in both treatment groups starting from approximately 12 weeks of treatment and continuing to plateau off over the remaining 12 weeks of the study.
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A numerical difference in the number of patients experiencing moderate/severe exacerbations (67 for the SFC group vs. 80 for the FBC group) over the 6-month treatment period was observed. Further analyses showed a 30% lower annualised rate of moderate/severe exacerbations for SFC than with FBC. This effect increased with time and became most prominent in the last 8 weeks of treatment, where there was a significant 57% difference in the moderate/severe exacerbation rate in favour of SFC (P ¼ 0:006). These findings are important for the clinician given the extensive morbidity and cost-implications associated with moderate/severe asthma exacerbations. 14 Both treatment groups showed a similar and clinically relevant improvement in lung function (PEF and FEV 1 ) from baseline to the end of treatment. Similar improvements in asthma symptoms and use of rescue medication were also shown in both treatment groups. These findings confirm, as with the Evaluation of Different Inhaled Combination Therapies (EDICT) study, 12 that regular, stable dose treatment at an appropriate ICS dose in the form of combination therapy can improve lung function and asthma symptoms even when patients are already receiving moderate-to-high doses of ICS. This phenomenon is well known and other studies have also shown the improvement over time with regular ICS therapy. 13 Regular treatment with inhaled budesonide over 9 months suppressed activation markers of eosinophils and neutrophils, and a higher dose of budesonide gave a superior effect, reduced exacerbations and progressively reduced bronchial hyperresponsiveness to inhaled histamine, supporting a time effect of ICS and a superior outcome with regular treatment. 15, 16 The significant difference in moderate/ severe exacerbation rates between SFC and FBC over time seen in this study may, in part, be due to differences in the molecular actions of the two treatments in this population of asthmatics and possibly also to differences in drug delivery between the Diskus/Accuhaler and the Turbuhaler. This was a fully blinded, double-dummy study and compliance with both inhaler devices was high so preference of the Diskus over the Turbuhaler by patients is unlikely to explain the difference in clinical outcomes over time in this study. Further research may help to explain the mechanisms behind the observations in the EXCEL study.
In conclusion, the data from this study showed that regular, twice-daily treatment with SFC and FBC over 6 months significantly improved asthma symptoms and lung function in the study population of adults with persistent asthma. The rate of exacerbations was also reduced over time on both treatments; however, SFC was found to be significantly superior to FBC in reducing the rate of moderate/severe exacerbations with regular, stable dose treatment.
